The impact of viral and host elements on HIV fitness and disease progression

Current HIV/AIDS Reports

Volumn 4, Issue 1, 2007, Pages 36-41

  Henry, Kenneth R ^b   Weber, Jan ^b   Quiñones Mateu, Miguel E ^b   Arts, Eric J ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; RANTES;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL DEATH; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SEXUAL TRANSMISSION; VIRUS ENVELOPE; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS TRANSMISSION;

ANTIGENS, CD4; CHEMOKINES; DISEASE PROGRESSION; GENE PRODUCTS, NEF; HIV; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRUS REPLICATION;

EID: 34147108761     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-007-0006-9     Document Type: Review

References (73)

1. Jung A, Maier R, Vartanian JP, et al.: Multiply infected spleen cells in HIV patients. Nature 2002, 418:144.
2. Mansky LM, Temin HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995, 69:5087-5094.
3. Lal RB, Chakrabarti S, Yang C: Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy and vaccine development. Indian J Med Res 2005, 121:287-314.
4. Domingo E, Holland JJ: RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997, 51:151-178.
5. Domingo E, Verdaguer N, Ochoa WF, et al.: Biochemical and structural studies with neutralizing antibodies raised against foot-and-mouth disease virus. Virus Res 1999, 62:169-175.
6. Troyer RM, Collins KR, Abraha A, et al.: Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005, 79:9006-9018. This study establishes a correlation between HIV fitness and disease progression.
7. Quinones-Mateu ME, Ball SC, Marozsan AJ, et al.: A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 2000, 74:9222-9233.
8. Lukashov VV, Goudsmit J: Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution? J Virol 1997, 71:2023-2030.
9. Nowak MA, Anderson RM, McLean AR, et al: Antigenic diversity thresholds and the development of AIDS. Science 1991, 254:963-969.
10. Nowak MA, May RM, Phillips RE, et al.: Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995, 375:606-611.
11. Delwart EL, Pan H, Sheppard HW, et al.: Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 1997, 71:7498-7508.
12. Wu H, Kuritzkes DR, McClernon DR, et al.: Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis 1999, 179:799-807.
13. Quinones-Mateu ME, Gao Y, Ball SC, et al.: In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms. J Virol 2002, 76:9600-9613.
14. Shankarappa R, Gupta P, Learn GH Jr, et al.: Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology 1998, 241:251-259.
15. Shankarappa R, Margolick JB, Gange SJ, et al.: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999, 73:10489-10502.
16. Clarke DK, Duarte EA, Elena SF, et al: The red queen reigns in the kingdom of RNA viruses. Proc Natl Acad Sci U S A 1994, 91:4821-4824.
17. Escarmis C, Cardilo EC, Ferrer M, et al.: Rapid selection in modified BHK-21 cells of a foot-and-mouth disease virus variant showing alterations in cell tropism. J Virol 1998, 72:10171-10179.
18. Novella IS, Duarte EA, Elena SF, et al.: Exponential increases of RNA virus fitness during large population transmissions. Proc Natl Acad Sci U S A 1995, 92:5841-5844.
19. Pantaleo G, Graziosi C, Fauci AS: The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993, 328:327-335.
20. Brenchley JM, Schacker TW, Ruff LE, et al.: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200:749-759.
21. Guadalupe M, Reay E, Sankaran S, et al.: Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003, 77:11708-11717.
22. Mehandru S, Poles MA, Tenner-Racz K, et al.: Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004, 200:761-770.
23. Picker LJ, Watkins DI: HIV pathogenesis: the first cut is the deepest. Nat Immunol 2005, 6:430-432.
24. Pierson TC, Doms RW: HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 2003, 281:1-27.
25. Poveda E, Briz V, Quinones-Mateu M, et al.: HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006, 20:1359-1367.
26. Ho DD: HIV-1 dynamics in vivo. J Biol Regul Homeost Agents 1995, 9:76-77.
27. Lazaro E, Escarmis C, Perez-Mercader J, et al.: Resistance of virus to extinction on bottleneck passages: study of a decaying and fluctuating pattern of fitness loss. Proc Natl Acad Sci U S A 2003, 100:10830- 10835.
28. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.
29. Martin MP, Dean M, Smith MW, et al.: Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998, 282:1907-1911.
30. Fortis C, Poli G: Dendritic cells and natural killer cells in the pathogenesis of HIV infection. Immunol Res 2005, 33:1-21.
31. Goodenow MM, Rose SL, Tuttle DL, et al.: HIV-1 fitness and macrophages. J Leukoc Biol 2003, 74:657-666.
32. Turville S, Wilkinson J, Cameron P, et al.: The role of dendritic cell C-type lectin receptors in HIV pathogenesis. J Leukoc Biol 2003, 74:710-718.
33. Valentin A, Pavlakis GN: Natural killer cells are persistently infected and resistant to direct killing by HIV-1. Anticancer Res 2003, 23:2071-2075.
34. Valentin A, Rosati M, Patenaude DJ, et al.: Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2002, 99:7015-7020.
35. Alkhatib G, Combadiere C, Broder CC, et al.: CC CKR5: a RANTES, MlP-lalpha, MlP-lbeta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
36. Amara A, Gall SL, Schwartz O, et al.: HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997, 186:139-146.
37. Aramori I, Ferguson SS, Bieniasz PD, et al.: Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. Embo J 1997, 16:4606-4616.
38. Arenzana-Seisdedos F, Virelizier JL, Rousset D, et al.: HIV blocked by chemokine antagonist. Nature 1996, 383:400.
39. Bleui CC, Farzan M, Choe H, et al.: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382:829-833.
40. Mack M, Schlondorff D: Downmodulation and recycling of chemokine receptors. Methods Mol Biol 2000, 138:191-195.
41. Gallo RC, Garzino-Demo A, DeVico AL: HIV infection and pathogenesis: what about chemokines? J Clin Immunol 1999, 19:293-299.
42. Gonzalez E, Kulkarni H, Bolivar H, et al.: The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005, 307:1434-1440. The study provides further evidence that host genetic alterations can impact HIV susceptibility particularly in the case of CCL3L1.
43. Cilliers T, Willey S, Sullivan WM, et al.: Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology 2005, 339:136-144.
44. Este JA, Cabrera C, Blanco J, et al.: Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing pheno-type by blockade of CXCR4. J Virol 1999, 73:5577-5585.
45. Mosier DE, Picchio GR, Gulizia RJ, et al.: Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999, 73:3544-3550.
46. Schols D, Este JA, Cabrera C, et al.: T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 1998, 72:4032-4037.
47. Torre VS, Marozsan AJ, Albright JL, et al.: Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol 2000, 74:4868-4876.
48. Karlsson I, Antonsson L, Shi Y, et al.: Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype. J Virol 2004, 78:11807-11815.
49. Carrington M, Nelson GW, Martin MP, et al.: HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999, 283:1748-1752.
50. Gao X, Nelson GW, Karacki P, et al.: Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001, 344:1668-1675.
51. Kaslow RA, Carrington M, Apple R, et al.: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996, 2:405-411.
52. Kamp W, Berk MB, Visser CJ, et al.: Mechanisms of HIV-1 to escape from the host immune surveillance. Eur J Clin Invest 2000, 30:740-746.
53. Allen TM, Altfeld M, Geer SC, et al.: Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005, 79:13239-13249.
54. Fernandez CS, Stratov I, De Rose R, et al.: Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol 2005, 79:5721-5731.
55. Friedrich TC, Dodds EJ, Yant LJ, et al.: Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 2004, 10:275-281.
56. Friedrich TC, Frye CA, Yant LJ, et al.: Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response. J Virol 2004, 78:2581-2585.
57. Martinez-Picado J, Prado JG, Fry EE, et al.: Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006, 80:3617-3623.
58. Troyer R, Abraha A, Krizan R, et al.: The fitness cost of CTL escape: not a terrible hardship on HIV-1? Paper presented at the XVI International AIDS Conference. Toronto, Canada; August 13-19, 2006.
59. Richman DD, Wrin T, Little SJ, et al.: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003, 100:4144-4149.
60. Arien KK, Gali Y, El-Abdellati A, et al.: Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones. Virology 2006, 347:65-74.
61. Ball SC, Abraha A, Collins KR, et al.: Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003, 77:1021-1038.
62. Marozsan AJ, Moore DM, Lobritz MA, et al.: Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 2005, 79:7121-7134.
63. Rangel HR, Weber J, Chakraborty B, et al.: Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J Virol 2003, 77:9069-9073.
64. Deacon NJ, Tsykin A, Solomon A, et al.: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991.
65. Kirchhoff F, Greenough TC, Brettler DB, et al.: Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995, 332:228-232.
66. Daniel MD, Kirchhoff F, Czajak SC, et al.: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258:1938-1941.
67. Schindler M, Munch J, Kutsch O, et al.: Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006, 125:1055-1067. Demonstrates the significance of nef in the downregulation of TCR-CD3 which inhibits T-cell activation and ultimately prevents cell death.
68. Quinones-Mateu ME, Arts EJ: Recombination in human immunodeficiency virus type-1 (HIV-1): update and implications. AIDS Review 1999, 1:89-100.
69. Konings FA, Burda ST, Urbanski MM, et al.: Human immunodeficiency virus type 1 (HIV-1) circulating recombinant form 02_AG (CRF02_AG) has a higher in vitro replicative capacity than its parental subtypes A and G. J Med Virol 2006, 78:523-534.
70. Quinones-Mateu ME, Arts EJ: Virus fitness: concept, quantification, and application to HIV population dynamics. Curr Top Microbiol Immunol 2006, 299:83-140.
71. Kimata JT, Kuller L, Anderson DB, et al.: Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 1999, 5:535-541.
72. Whetter LE, Ojukwu IC, Novembre FJ, et al.: Pathogenesis of simian immunodeficiency virus infection. J Gen Virol 1999, 80:1557-1568.
73. Holterman L, Niphuis H, Koornstra W, et al.: The rate of progression to AIDS is independent of virus dose in simian immunodeficiency virus-infected macaques. J Gen Virol 2000, 81:1719-1726.